Advertisement

Topics

Cardinal Health Reports Q4 and Fiscal 2017 Results, Provides 2018 Guidance

03:13 EDT 2 Aug 2017 | PR Newswire

DUBLIN, Ohio, Aug. 2, 2017 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth-quarter fiscal year 2017 revenues of $33 billion, an increase of 5 percent from the fourth quarter last year, and fiscal 2017 revenues of $130 billion, an increase of 7 percent from the same period last year. For the quarter, GAAP diluted earnings per share (EPS) decreased 16 percent to $0.86, while non-GAAP diluted EPS increased 15 percent to $1.31. GAAP diluted EPS for fiscal year 2017 decreased 7 percent to $4.03, and non-GAAP diluted EPS increased 3 percent to $5.40.

"While these last 12 months were clearly a dynamic period in healthcare and certainly presented challenges for our fiscal 17, it was also a year in which we took important actions to strengthen our market positioning, grow our scale, add new, long-term drivers of growth, and improve the overall balance of our integrated portfolio," said George Barrett, chairman and CEO of Cardinal Health. "In spite of the challenges of the year, our team was able to deliver growth in non-GAAP EPS."

Q4 and year-end FY17 summary

Q4 FY17

Q4 FY16

Y/Y

FY17

FY16

Y/Y

Revenue

$33.0 billion

$31.4 billion

5%

$130.0 billion

$121.5 billion

7%

Operating
earnings

 

$439 million

 

$620 million

(29%)

 

$2,120 million

 

$2,459 million

(14%)

Non-GAAP
operating
earnings

 

$640 million

 

$643 million

(1%)

 

$2,769 million

 

$2,895 million

(4%)

Net earnings
attributable to
Cardinal Health, Inc.

 

$274 million

 

$333 million

(18%)

 

$1,288 million

 

$1,427 million

(10%)

Non-GAAP net
earnings attributable to
Cardinal Health, Inc.

 

$416 million

 

$372 million

12%

 

$1,727 million

 

$1,732 million

-

Diluted EPS
attributable to
Cardinal Health, Inc.

$0.86

$1.02

(16%)

$4.03

$4.32

(7%)

Non-GAAP
diluted EPS
attributable to
Cardinal Health, Inc.

$1.31

$1.14

15%

$5.40

$5.24

3%

Diluted EPS for the quarter and year benefitted from a lower effective tax rate and fewer weighted average shares outstanding than the prior-year periods.

Segment results

Pharmaceutical segment

Fourth-quarter revenue for the Pharmaceutical segment increased 5 percent to $29.6 billion due to growth from Pharmaceutical Distribution customers and strong performance from the Specialty Solutions business. Segment profit decreased 7 percent to $505 million. This decrease was driven by generic pharmaceutical pricing and the company's ongoing investment in its Pharmaceutical IT platform. These were partially offset by solid performance from Red Oak Sourcing.

Full-year revenue for the Pharmaceutical segment increased 7 percent to $116.5 billion due to growth from Pharmaceutical Distribution customers and strong performance from the Specialty Solutions business. Segment profit for the year decreased 12 percent to $2.2 billion driven by generic pharmaceutical pricing, and to a lesser extent, the impact of the loss of Safeway and reduced levels of branded manufacturer price appreciation. These were partially offset by solid performance from Red Oak Sourcing.

Q4 FY17

Q4 FY16

Y/Y

FY17

FY16

Y/Y

Revenue

$29.6 billion

$28.2 billion

5%

$116.5 billion

$109.1 billion

7%

Segment profit

$505 million

$542 million

(7%)

$2.2 billion

$2.5 billion

(12%)

Medical segment

Revenue for the Medical segment increased 6 percent to $3.4 billion driven by contributions from new and existing customers. Segment profit increased 13 percent to $138 million reflecting solid performance from post-acute solutions, favorability from compensation-related items and growth in distribution services. These were partially offset by performance in Cardinal Health Branded products (including Cordis).

Full-year revenue for the Medical segment increased 9 percent to $13.5 billion due to contributions from new and existing customers and, to a lesser extent, acquisitions. Segment profit increased 25 percent to $572 million due to the contribution from post-acute solutions, Cardinal Health Branded products (including Cordis), favorability from compensation-related items and growth in distribution services.

Q4 FY17

Q4 FY16

Y/Y

FY17

FY16

Y/Y

Revenue

$3.4 billion

$3.2 billion

6%

$13.5 billion

$12.4 billion

9%

Segment profit

$138 million

$122 million

13%

$572 million

$457 million

25%

Outlook

The company does not provide GAAP EPS outlook because it is unable to reliably forecast most of the items that are excluded from GAAP EPS to calculate non-GAAP EPS. These items could cause EPS to differ materially from non-GAAP EPS. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

The company's fiscal year 2018 guidance range for non-GAAP diluted EPS from continuing operations is $4.85 to $5.10. This guidance now reflects incremental discrete items of $0.16 per share, identified since the early outlook announcement provided in April.

In a further comment on the year ahead, Barrett said: "As we indicated in our April early outlook, we expected our fiscal 2018 non-GAAP EPS to be down. Our perspective and operating expectations have not meaningfully changed. We are, however, taking some discrete actions, which will affect our EPS in FY18 and will improve our trajectory for 2019 and beyond. And we are targeting fiscal 2019 non-GAAP EPS of at least $5.60."

FY17 and recent highlights

  • Completed the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion on July 29, 2017
  • Acquired rights to Navidea's Lymphoseek, a radiopharmaceutical diagnostic imaging agent
  • Convened the 27th annual Retail Business Conference, which provided one of the industry's largest lineups of continuing education courses, buying opportunities, and access to Cardinal Health solutions that help independent pharmacists diversify and improve their business
  • Through the Cordis business, became the exclusive U.S. distributor of the Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the U.S. to treat significant coronary bifurcation lesions
  • Increased quarterly dividend by 3 percent to $0.4624 per share, or $1.85 on an annualized basis

Awards and recognition

Over the past year, Cardinal Health was recognized for its leadership and commitment to diversity and sustainability, including:

Webcast

Cardinal Health will host a webcast today at 8:30 a.m. Eastern to discuss fourth-quarter and year-end results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. 

Presentation slides and a webcast replay will be available on the Cardinal Health website at ir.cardinalhealth.com until Aug. 1, 2018.

Upcoming webcasted investor events

  • Robert W. Baird's Global Healthcare Conference on Thursday, Sept. 7 at 9:05 a.m. Eastern in New York City
  • Morgan Stanley 15th Annual Global Healthcare Conference on Monday, Sept. 11 at 8:45 a.m. Eastern in New York City

About Cardinal Health Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Because Cardinal Health helps ensure pharmacists and the consumers they serve have access to medications they need while working to help prevent prescription drug diversion, the company and its education partners created Generation Rx, a national program to help prevent the misuse of prescription medications. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #15 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter and connect on LinkedIn at linkedin.com/ company/cardinal-health.

1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP.  See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release, and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions concerning forward-looking statements This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the amount or rate of pharmaceutical price appreciation or deflation and the timing of and benefit from generic pharmaceutical introductions; the ability to maintain the benefits from the generic sourcing venture with CVS Health; risks associated with the recently completed acquisition of Medtronic's Patient Recovery Business, including the ability to retain the acquired businesses' customers and employees, the ability to successfully integrate the acquired businesses into our operations and the ability to achieve the expected synergies as well as accretion in earnings; the risk of non-renewal or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties due to government health care reform including proposals to modify or repeal the Affordable Care Act; uncertainties with respect to U.S. tax or trade laws, including proposals relating to a "border adjustment tax" or new import tariffs; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any governmental or regulatory authority, including litigation relating to opioid distribution; and changes in foreign currency rates and the cost of commodities such as oil-based resins, cotton, latex and diesel fuel. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of August 2, 2017. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.

Schedule 1

Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Statements of Earnings (Unaudited)

Fourth Quarter

(in millions, except per common share amounts)

2017

2016

% Change

Revenue

$

32,966

$

31,384

5

%

Cost of products sold

31,343

29,719

5

%

Gross margin

1,623

1,665

(3)

%

Operating expenses:

Distribution, selling, general and administrative expenses

983

970

1

%

Restructuring and employee severance

24

6

N.M.

Amortization and other acquisition-related costs

163

132

N.M.

Impairments and loss on disposal of assets, net

3

3

N.M.

Litigation (recoveries)/charges, net

11

(66)

N.M.

Operating earnings

439

620

(29)

%

Other (income)/expense, net

(3)

N.M.

Interest expense, net

68

44

55

%

Earnings before income taxes

374

576

(35)

%

Provision for income taxes

96

241

(60)

%

Net earnings

278

335

(17)

%

Less: Net earnings attributable to noncontrolling interests

(4)

(2)

N.M.

Net earnings attributable to Cardinal Health, Inc.

$

274

$

333

(18)

%

Earnings per common share attributable to Cardinal Health, Inc.:

Basic

$

0.87

$

1.03

(16)

%

Diluted

0.86

1.02

(16)

%

Weighted-average number of common shares outstanding:

Basic

316

324

Diluted

318

327

Schedule 2

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (Unaudited)

Fiscal Year

(in millions, except per common share amounts)

2017

2016

% Change

Revenue

$

129,976

$

121,546

7

%

Cost of products sold

123,432

115,003

7

%

Gross margin

6,544

6,543

%

Operating expenses:

Distribution, selling, general and administrative expenses

3,775

3,648

3

%

Restructuring and employee severance

56

25

N.M.

Amortization and other acquisition-related costs

527

459

N.M.

Impairments and loss on disposal of assets, net

18

21

N.M.

Litigation (recoveries)/charges, net

48

(69)

N.M.

Operating earnings

2,120

2,459

(14)

%

Other (income)/expense, net

(5)

5

N.M.

Interest expense, net

201

178

13

%

Earnings before income taxes

1,924

2,276

(15)

%

Provision for income taxes

630

845

(25)

%

Net earnings

1,294

1,431

(10)

%

Less: Net earnings attributable to noncontrolling interests

(6)

(4)

N.M.

Net earnings attributable to Cardinal Health, Inc.

$

1,288

$

1,427

(10)

%

Earnings per common share attributable to Cardinal Health, Inc.:

Basic

$

4.06

$

4.36

(7)

%

Diluted

4.03

4.32

(7)

%

Weighted-average number of common shares outstanding:

Basic

317

327

Diluted

320

330

Schedule 3

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

(in millions)

June 30,
 2017

June 30,
 2016

Assets

Current assets:

Cash and equivalents

$

6,879

$

2,356

Trade receivables, net

8,048

7,405

Inventories, net

11,301

10,615

Prepaid expenses and other

2,117

1,580

Total current assets

28,345

21,956

Property and equipment, net

1,879

1,796

Goodwill and other intangibles, net

9,207

9,426

Other assets

681

944

Total assets

$

40,112

$

34,122

Liabilities, Redeemable Noncontrolling Interests and Shareholders' Equity

Current liabilities:

Accounts payable

$

17,906

$

17,306

Current portion of long-term obligations and other short-term borrowings

1,327

587

Other accrued liabilities

1,988

1,808

Total current liabilities

21,221

19,701

Long-term obligations, less current portion

9,068

4,952

Deferred income taxes and other liabilities

2,877

2,781

Redeemable noncontrolling interests

118

117

Total Cardinal Health, Inc. shareholders' equity

6,808

6,554

Noncontrolling interests

20

17

Total shareholders' equity

6,828

6,571

Total liabilities, redeemable noncontrolling interests and shareholders' equity

$

40,112

$

34,122


Schedule 4

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)

Fourth Quarter

Fiscal Year

(in millions)

2017

2016

2017

2016

(Unaudited)

(Unaudited)

(Unaudited)

Cash flows from operating activities:

Net earnings

$

278

$

335

$

1,294

$

1,431

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization

192

176

717

641

Gain on sale of other investments

4

Gain on disposal of assets, net

3

4

18

21

Share-based compensation

23

29

96

111

Provision for deferred income taxes

291

87

291

87

Provision for bad debts

17

22

63

73

Change in fair value of contingent consideration obligation

(5)

(5)

(16)

Change in operating assets and liabilities, net of effects from acquisitions:

Increase in trade receivables

(558)

(145)

(665)

(866)

Decrease/(increase) in inventories

337

278

(673)

(1,179)

Increase/(decrease) in accounts payable

329

(24)

564

2,815

Other accrued liabilities and operating items, net

(183)

(121)

(520)

(147)

Net cash provided by operating activities

724

641

1,184

2,971

Cash flows from investing activities:

Acquisition of subsidiaries, net of cash acquired

(19)

(231)

(132)

(3,614)

Additions to property and equipment

(94)

(181)

(387)

(465)

Purchase of available-for-sale securities and other investments

(6)

(50)

(194)

(200)

Proceeds from sale of available-for-sale securities and other investments

113

37

228

136

Proceeds from maturities of available-for-sale securities

28

13

77

50

Proceeds from divestitures and disposal of property and equipment and held for sale assets

2

13

3

13

Net cash provided by/(used in) investing activities

24

(399)

(405)

(4,080)

Cash flows from financing activities:

Payment of contingent consideration obligation

(2)

(3)

(25)

Net change in short-term borrowings

(22)

(8)

3

26

Net purchase of noncontrolling interests

(12)

(10)

Reduction of long-term obligations

(250)

(1)

(310)

(6)

Proceeds from interest rate swap terminations

14

Proceeds from long-term obligations, net of issuance costs

5,171

5,171

Net tax proceeds/(withholdings) from share-based compensation

6

9

26

6

Excess tax benefits from share-based compensation

(3)

34

33

Dividends on common shares

(142)

(126)

(577)

(512)

Purchase of treasury shares

(351)

(600)

(651)

Net cash provided by/(used in) financing activities

4,760

(479)

3,746

(1,139)

Effect of exchange rates changes on cash and equivalents

3

(5)

(2)

(12)

Net increase/(decrease) in cash and equivalents

5,511

(242)

4,523

(2,260)

Cash and equivalents at beginning of period

1,368

2,598

2,356

4,616

Cash and equivalents at end of period

$

6,879

$

2,356

$

6,879

$

2,356

Schedule 5

Cardinal Health, Inc. and SubsidiariesSegment Business Analysis

Fourth Quarter

Fourth Quarter

(in millions)

2017

2016

(in millions)

2017

2016

Pharmaceutical

Medical

Revenue

Revenue

Amount

$

29,552

$

28,177

Amount

$

3,416

$

3,210

Growth rate

5

%

14

%

Growth rate

6

%

12

%

Segment profit

Segment profit

Amount

$

505

$

542

Amount

$

138

$

122

Growth rate

(7)

%

1

%

Growth rate

13

%

19

%

Segment profit margin

1.71

%

1.93

%

Segment profit margin

4.03

%

3.81

%

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the three months ended June 30, 2017 was $32,966 million, which included total segment revenue of $32,968 million and Corporate revenue of $(2) million. Total consolidated revenue for the three months ended June 30, 2016 was $31,384 million, which included total segment revenue of $31,387 million and Corporate revenue of $(3) million. Corporate revenue consists primarily of elimination of inter-segment revenue and other revenue not allocated to the segments.

Total consolidated operating earnings for the three months ended June 30, 2017 were $439 million, which included total segment profit of $643 million and Corporate costs of $(204) million. Total consolidated operating earnings for the three months ended June 30, 2016 were $620 million, which included total segment profit of $664 million and Corporate costs of $(44) million. Corporate includes, among other things, LIFO charges/(credits), restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments. The increase in corporate costs is primarily due to the change in ligation (recoveries)/charges, net driven by the lack of litigation recoveries from the prior period recurring in the current period and the prior year LIFO credits that did not recur in the current period.


Schedule 6

Cardinal Health, Inc. and SubsidiariesSegment Business Analysis

Fiscal Year

Fiscal Year

(in millions)

2017

2016

(in millions)

2017

2016

Pharmaceutical

Medical

Revenue

Revenue

Amount

$

116,463

$

109,131

Amount

$

13,524

$

12,430

Growth rate

7

%

20

%

Growth rate

9

%

9

%

Segment profit

Segment profit

Amount

$

2,187

$

2,488

Amount

$

572

$

457

Growth rate

(12)

%

19

%

Growth rate1

25

%

6

%

Segment profit margin

1.88

%

2.28

%

Segment profit margin

4.23

%

3.68

%

1.   

Segment profit for the fiscal year ended June 30, 2016 includes the $43 million unfavorable impact of the Cordis-related inventory fair value step-up. Excluding this step-up, year-over-year Medical segment profit growth was 14 percent and 15 percent for the fiscal years ended June 30, 2017 and 2016, respectively.

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the fiscal year ended June 30, 2017 was $129,976 million, which included total segment revenue of $129,987 million and Corporate revenue of $(11) million. Total consolidated revenue for the fiscal year ended June 30, 2016 was $121,546 million, which included total segment revenue of $121,561 million and Corporate revenue of $(15) million.  Corporate revenue consists primarily of elimination of inter-segment revenue and other revenue not allocated to the segments.

Total consolidated operating earnings for the fiscal year ended June 30, 2017 were $2,120 million, which included total segment profit of $2,759 million and Corporate costs of $(639) million. Total consolidated operating earnings for the fiscal year ended June 30, 2016 were $2,459 million, which included total segment profit of $2,945 million and Corporate costs of $(486) million. Corporate includes, among other things, LIFO charges/(credits), restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments.

Schedule 7

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation1

Gross

Operating

Earnings

Provision

Margin

Earnings

Before

for

Net

Diluted

Gross

Growth

Operating

Growth

Income

Income

Net

Earnings2

Diluted

EPS2

(in millions, except per common share
amounts)

Margin

Rate

Earnings

Rate

Taxes

Taxes

Earnings2

Growth Rate

EPS2,3,4

Growth Rate

Fourth Quarter 2017

GAAP

$

1,623

(3)

%

$

439

(29)%

$

374

$

96

$

274

(18)

%

$

0.86

(16)

%

Restructuring and employee severance

24

24

9

15

0.05

Amortization and other acquisition-related costs

163

163

45

118

0.37

Impairments and (gain)/loss on disposal of assets

3

3

1

2

0.01

Litigation (recoveries)/charges, net

11

11

4

7

0.02

Non-GAAP

$

1,623

1

%

$

640

(1)%

$

575

$

155

$

416

12

%

$

1.31

15

%

Fourth Quarter 2016

GAAP

$

1,665

14

%

$

620

11

%

$

576

$

241

$

333

14

%

$

1.02

16

%

LIFO charges/(credits)

(51)

(51)

(51)

(20)

(31)

(0.10)

Restructuring and employee severance

6

6

2

4

0.01

Amortization and other acquisition-related costs

132

132

28

104

0.32

Impairments and (gain)/loss on disposal of assets

3

3

3

0.01

Litigation (recoveries)/charges, net

(66)

(66)

(25)

(41)

(0.13)

Non-GAAP

$

1,614

11

%

$

643

5

%

$

599

$

226

$

372

12

%

$

1.14

14

%

Gross

Operating

Earnings

Provision

Margin

Earnings

Before

for

Net

Diluted

Gross

Growth

Operating

Growth

Income

Income

Net

Earnings2

Diluted

EPS2

(in millions, except per common share
amounts)

Margin

Rate

Earnings

Rate

Taxes

Taxes

Earnings2

Growth Rate

EPS2,3,4

Growth Rate

Fiscal Year 2017

GAAP

$

6,544

$

$

2,120

(14)%

$

1,924

$

630

$

1,288

(10)

%

$

4.03

(7)

%

Restructuring and employee severance

56

56

20

36

0.11

Amortization and other acquisition-related costs

527

527

165

362

1.13

Impairments and (gain)/loss on disposal of assets

18

18

6

12

0.04

Litigation (recoveries)/charges, net

48

48

19

29

0.09

Non-GAAP

$

6,544

%

$

2,769

(4)%

$

2,572

$

839

$

1,727

%

$

5.40

3

%

Fiscal Year 2016

GAAP

$

6,543

15

%

$

2,459

14

%

$

2,276

$

845

$

1,427

18

%

$

4.32

20

%

Restructuring and employee severance

25

25

9

16

0.05

Amortization and other acquisition-related costs

459

459

143

316

0.96

Impairments and (gain)/loss on disposal of assets

21

21

6

15

0.04

Litigation (recoveries)/charges, net

(69)

(69)

(27)

(42)

(0.13)

Non-GAAP

$

6,543

15

%

$

2,895

17

%

$

2,711

$

976

$

1,732

18

%

$

5.24

20

%

1For more information on these measures, refer to the Use of Non-GAAP Financial Measures and Definitions schedules.

2attributable to Cardinal Health, Inc.

3GAAP diluted EPS for the three months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.21, which includes  $0.19 due to change in the effective tax rate and $0.02 due to the change in weighted average shares outstanding. GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.39, which includes $0.26 due to change in the effective tax rate and $0.13 due to the change in weighted average shares outstanding. The change in GAAP diluted EPS due to the effective tax rate is calculated as ((GAAP Earnings before Income Taxes for the current period times (one minus the current period GAAP Effective Tax Rate)) minus (GAAP Earnings before Income Taxes for the current period times (one minus the prior period GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in GAAP diluted EPS due to the weighted average shares outstanding is calculated as (GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding).

4Non-GAAP diluted EPS for the three months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.22, which includes $0.19  due to change in the effective tax rate and $0.03 due to the change in weighted average shares outstanding. Non-GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.44, which includes $0.27 due to change in the effective tax rate and $0.17 due to the change in weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the effective tax rate is calculated as ((Non-GAAP Earnings before Income Taxes for the current period times (one minus the current period Non-GAAP Effective Tax Rate)) minus (Non-GAAP Earnings before Income Tax for the current period times (one minus the prior period Non-GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the weighted average shares outstanding is calculated as (Non-GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (Non-GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding).

The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

There were no losses on extinguishment of debt during the periods presented.

Schedule 8 

Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation

Fourth Quarter

Fiscal Year

(in millions)

2017

2016

2017

2016

GAAP effective tax rate

25.8

%

41.8

%

32.7

%

37.1

%

Non-GAAP effective tax rate

Earnings before income taxes

$

374

$

576

$

1,924

$

2,276

LIFO charges/(credits)

(51)

Restructuring and employee severance

24

6

56

25

Amortization and other acquisition-related costs

163

132

527

459

Impairments and loss on disposal of assets

3

3

18

21

Litigation (recoveries)/charges, net

11

(66)

48

(69)

Adjusted earnings before income taxes

$

575

$

599

$

2,572

$

2,711

Provision for income taxes

$

96

$

241

$

630

$

845

LIFO charges/(benefits) tax benefit/(expense)

(20)

Restructuring and employee severance tax benefit

9

2

20

9

Amortization and other acquisition-related costs tax benefit

45

28

165

143

Impairments and loss on disposal of assets tax benefit

1

6

6

Litigation (recoveries)/charges, net tax benefit/(expense)

4

(25)

19

(27)

Adjusted provision for income taxes

$

155

$

226

$

839

$

976

Non-GAAP effective tax rate

27.0

%

37.6

%

32.6

%

36.0

%

The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Cardinal Health, Inc. and Subsidiaries

Use of Non-GAAP Measures

This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.

Exclusions from Non-GAAP Financial Measures

Management believes it is useful to exclude the following items from the non-GAAP measures presented in this earnings release for its own and for investors' assessment of the business for the reasons identified below:

  • LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges from non-GAAP metrics allows for a better comparison of our current financial results to our historical financial results and to our peer group companies' financial results.
  • Restructuring and employee severance costs are excluded because they relate to programs in which we fundamentally change our operations and because they are not part of the ongoing operations of our underlying business.
  • Amortization and other acquisition-related costs are excluded primarily for consistency with the presentation of the financial results of our peer group companies. Additionally, costs for amortizations of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion allows for better comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs because they are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. They are also significantly impacted by the timing and size of acquisitions.
  • Impairments and gains or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and their exclusion results in a metric that more meaningfully reflects the sustainability of our operating performance.
  • Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, and are inherently unpredictable in timing and amount. In the third quarter of fiscal 2017, consistent with the presentation of financial results by peer medical device companies, in litigation recoveries or charges, net we began to classify accrued losses and legal fees, net of expected recoveries, related to mass tort product liability claims, including claims for injuries allegedly caused by Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Such amounts would not have materially affected litigation recoveries or charges, net in prior periods, so have not been reclassified for those periods.
  • Loss on extinguishment of debt is excluded because it does not typically occur in the normal course of business operations and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt financing transactions.

The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Forward Looking Non-GAAP Measures

In this earnings release, the Company presents its outlook for fiscal 2018 non-GAAP EPS.  The Company does not provide EPS outlook, which is the most directly comparable GAAP measure to non-GAAP EPS, because changes in the items that the Company excludes from EPS to calculate non-GAAP EPS, described above, can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, due to their unpredictability, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an EPS outlook. For fiscal 2018, the Company expects the acquisition of the Patient Recovery Business to significantly increase amortization and other acquisition-related costs.

The timing and amount of any of the excluded items could significantly impact the Company's fiscal 2018 EPS. Over the past five fiscal years, the excluded items have lowered the Company's EPS from $0.47 to $2.76, which includes a goodwill impairment charge of $2.32 per share related to our Nuclear Pharmacy Services division that we recognized in fiscal 2013.

Definitions


Growth rate calculation: Growth rates in this earnings release are determined by dividing the difference between current period results and prior period results by prior period results.

Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets and (5) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5) litigation (recoveries)/charges, net and (6) loss on extinguishment of debt.

Non-GAAP effective tax rate: (provision for income taxes adjusted for (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5)  litigation (recoveries)/charges, net, and (6) loss on extinguishment of debt) divided by (earnings before income taxes adjusted for the same six items).

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5) litigation (recoveries)/charges, net and (6) loss on extinguishment of debt, each net of tax.

Non-GAAP diluted EPS attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

View original content:http://www.prnewswire.com/news-releases/cardinal-health-reports-q4-and-fiscal-2017-results-provides-2018-guidance-300498210.html

SOURCE Cardinal Health

NEXT ARTICLE

More From BioPortfolio on "Cardinal Health Reports Q4 and Fiscal 2017 Results, Provides 2018 Guidance"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...